Even after its latest sharp fall, the drugmaker’s stock price assumes wild successes.

A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients' tumors come back, according ...

Moderna's stock plunged on Thursday, startling investors. But the company remains one of this year’s hottest biotech ...

Moderna gave investors a scare as its stock plunged on Thursday. But it's still one of the hottest biotechs this year. And it's hardly alone – the sector is on a roll and looks poised for more gains.

Pfizer reports strong Phase 2 data for its 25-valent pediatric pneumococcal vaccine, showing superior immune response against serotype 3 compared to ...

Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with ...

One man's journey with breast cancer ...

Elon Musk says SpaceX limited Starlink access after Ukraine used it in offensive drone strikes; speeds later restored and U.S ...

Braskem shared an updated business plan and competing proposals for an $11B out-of-court debt rework; talks with investors ...

Moderna and Merck's personalized mRNA vaccine reduced melanoma recurrence/death risk by 42% in Phase 3 trials, but Moderna's ...

Until this moment, Senator, I think I never really gauged your cruelty, or your recklessness.” ...